Clinical trials: Decompensated Cirrhosis
Decompensated Cirrhosis
Hospital @ Home Model of Care for Cirrhosis
The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and…
- Trial name
- H@H (NCT06396897)
- Testing
- Indiana University Health Hospital at Home Program
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Liver Cirrhoses
Concordance Between Echocardiographic Assessment Performed in the Initial Phase of Decompensated Cirrhosis With Edema and Ascites by an Expert Intensive Care Physician and a Non-expert Gastroenterologist
The investigators hypothesize that trans-thoracic ultrasound performed by non-specialist gastroenterologists with a standard training by intensive care doctors will give equivalent results to those achieved by experts for a…
- Trial name
- EchoCirrho (NCT03650660)
- Testing
- Trans-thoracic ultrasound
- Where
- France
- Volunteers
- 55 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Cirrhosis
Mesenchymal Stem Cell Transplantation in Decompensated Cirrhosis
The standard treatment for decompensated cirrhosis is liver transplantation, however, it has several limitations. Recent animal studies suggest that bone marrow stem cell transplantation can lead to regression of liver fibrosis.
- Trial name
- NCT00476060
- Testing
- Autologous mesenchymal stem cell transplantation
- Where
- Iran
- Volunteers
- 27 people
- Sponsor
- University of Tehran
Decompensated Cirrhosis and Ascites
Personalized Long-term Human Albumin Treatment in Patients With Decompensated Cirrhosis and Ascites
The goal of this clinical biomarker validation trial is to test the effect of a predictive biomarker panel to human albumin infusions in patients with liver cirrhosis and ascites.
- Trial name
- NCT05056220
- Testing
- Human albumin, sodium chloride
- Where
- 12 sites in Belgium, Denmark and 5 more
- Volunteers
- 240 people
- Sponsor
- Aleksander Krag
Liver Cirrhosis
Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis
The primary objective of this study is to assess the efficacy of rifaximin SSD versus placebo in preventing complications of liver cirrhosis, such as all-cause mortality (death due to all causes) or hospitalization, in subjects…
- Trial name
- NCT01904409
- Testing
- Rifaximin SSD 40 mg IR tablet, Rifaximin SSD 80 mg IR tablet, Rifaximin SSD 40 mg SER tablet
- Where
- 120 sites in United States, Russia
- Volunteers
- 420 people
- Sponsor
- Bausch Health Americas, Inc.
Decompensated Cirrhosis
Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-1)
This is a Phase 1, open label, dose escalation clinical trial of human umbilical cord-derived mesenchymal stem cells for the treatment of decompensated cirrhosis.
- Trial name
- NCT05227846
- Testing
- Human Umbilical Cord-derived Mesenchymal Stem Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing 302 Hospital
Liver Cirrhosis, Alcoholic, Progression
Prospective Cohort Study of Disease and Outcomes in Cirrhosis
A population based incidence cohort will enroll patients newly diagnosed with cirrhosis to investigate disease characteristics and outcomes, explore mechanisms predicting early death and hospital admission, and assess new…
- Conditions
- Liver Cirrhosis, Alcoholic, Progression, Liver Diseases, Decompensated Cirrhosis
- Trial name
- ProDoc (NCT04422223)
- Where
- Denmark
- Volunteers
- 550 people
- Sponsor
- Copenhagen University Hospital, Hvidovre
Decompensated Cirrhosis
National Collaborative Centre for Hepatic Regenerative Medicine (NC-CHRM): Single vs Repeated Cycle of Granulocyte Colony-Stimulating Factor (GCSF) & Darbepoetin in Early Decompensated Cirrhosis
Chronic liver disease is a growing health concern, with limited access to liver transplants. This study addresses the urgent need for alternatives by exploring regenerative therapies, like G-CSF, to boost the liver's natural…
- Trial name
- NC-CHRM (NCT07131280)
- Testing
- Gcsf, Darbepoetin, Standard Medical Treatment
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Liver Cirrhosis
Study in Patients With Decompensated Liver Cirrhosis
OPAL is a multicenter observational study, following the natural disease trajectory of participants who have permanent damage to their liver caused by scarring, sometimes also referred to as liver cirrhosis.
- Trial name
- OPAL (NCT06380335)
- Where
- 12 sites in Spain, United Kingdom
- Volunteers
- 24 people
- Sponsor
- Resolution Therapeutics Limited
Liver Cirrhosis, Experimental
Antiviral Therapy in Decompensated Hepatitis C Virus (HCV) Cirrhosis
To evaluate: 1. the impact of combined antiviral therapy (Peginterferon plus ribavirin) on natural history of patients affected with HCV decompensated cirrhosis, after sustained virological response. A controlled study. 2.
- Trial name
- NCT00301509
- Testing
- peginterferon and ribavirin
- Where
- Italy
- Volunteers
- healthy volunteers welcome
- Sponsor
- Casa Sollievo della Sofferenza IRCCS
Decompensated Cirrhosis, CMV Reactivation
Prospective Cohort Study of Complications and Outcomes in Cirrhosis
This is a multi-center, nested cohort study intended to investigate the prevalence, risk factors, and outcomes of complications in patients with acutely decompensated cirrhosis, especially focused on Cytomegalovirus (CMV)…
- Conditions
- Decompensated Cirrhosis, CMV Reactivation, Overt Hepatic Encephalopathy
- Trial name
- NCT06374511
- Testing
- Test for CMV reactivation
- Where
- China
- Volunteers
- 660 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Cirrhosis
PiCCO Guided Therapy in Liver Cirrhosis
Prospective comparison of standard therapy in liver cirrhosis versus standard therapy plus intensified hemodynamic monitoring using the PiCCO system.
- Trial name
- NCT00232427
- Testing
- Hemodynamic monitoring system PiCCO
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Heidelberg University
Portal Hypertension
The Effect of Probiotics (VSL) on Portal Hypertension
The investigators will address the hypothesis that portal hypertension is mediated in part by bacterial or endotoxin translocation and the production of inflammatory mediators (tumor necrosis factor-α (TNFα), etc.).
- Trial name
- NCT01032941
- Testing
- Probiotic
- Where
- Canada
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Alberta
Decompensated Liver Cirrhosis
Effect of Single vs Repeated Cycles of a Combination of Granulocyte Colony Stimulating Factor and Darbepoetin vs Standard Medical Treatment on Immunometabolic Profile in Patient With Early Decompensated Cirrhosis.
Exogenous growth factor-mobilized bone marrow (BM) stem cells(G-CSF) and DARBEPOETIN use have shown a differential response in the management of decompensated cirrhosis (DC) with improved survival, CTP and MELD scores.
- Trial name
- NCT07002827
- Testing
- Darbepoetin, G-CSF, Lactulose
- Where
- India
- Volunteers
- 60 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Decompensated Cirrhosis
CirrhoCare- Using Smart-phone Technology to Enhance Care and Access to Treatment for Cirrhosis
The CirrhoCare trial is a multi-centre, open label randomised controlled trial in patients with decompensated cirrhosis. The trial aims to investigate the clinical and cost-effectiveness of CirrhoCare digital home monitoring and…
- Trial name
- CirrhoCare (NCT06223893)
- Testing
- CirrhoCare management system
- Where
- 15 sites in United Kingdom
- Volunteers
- 214 people
- Sponsor
- University College, London
Decompensated Cirrhosis and Ascites
Effects of Long-Term Administration of Human Albumin in Participants With Decompensated Cirrhosis and Ascites
This is a phase 3, multicenter, randomized, controlled, parallel-group, and open-label clinical study to evaluate the efficacy of standard medical treatment (SMT) + Albutein 20% administration versus SMT alone in participants…
- Trial name
- PRECIOSA (NCT03451292)
- Testing
- Albutein 20%, SMT
- Where
- 66 sites in United States, Belgium and 12 more
- Volunteers
- 410 people
- Sponsor
- Grifols Therapeutics LLC
Liver Cirrhosis
Fecal Microbiota Transplantation in Decompensated Cirrhosis
Cirrhosis of the liver is the culmination point of long-standing chronic liver disease hallmarked by the cardinal features of liver fibrosis and portal hypertension.
- Trial name
- NCT04842539
- Testing
- Fecal Microbiota Transplantation, Standard of care
- Where
- India
- Volunteers
- 36 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
Decompensated Cirrhosis, Ascites
VSL#3 and Spontaneous Bacterial Peritonitis
Research question: Do oral probiotics in patients with cirrhosis and ascites reduce intestinal bacterial concentrations, ascitic bacterial DNA, SBP and bacteraemia compared to antibiotics or placebo? This study is designed to…
- Trial name
- NCT01701297
- Testing
- cotrimoxazole, VSL#3 active
- Where
- United Kingdom
- Volunteers
- 10 people
- Sponsor
- Nottingham University Hospitals NHS Trust
Cirrhosis, Liver, AKI
Dextran, a Plasma Expander, Offers New Hope for Patients With Decompensated Liver Cirrhosis and Acute Kidney Injury
A pilot study of Dextran-40 infusion in patients with decompensated cirrhosis presenting with AKI
- Trial name
- NCT03070353
- Testing
- Dextran 40
- Volunteers
- 10 people
- Sponsor
- Ramathibodi Hospital
Hepatitis B, Cirrhosis
A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.
This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection.
- Trial name
- NCT00275652
- Testing
- LdT (Telbivudine) and lamivudine
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mayo Clinic